Alembic pharmaceuticals Limited has announced the sad demise of Mr. Saibal Mukherjee, Resident Director (Delhi Office), who passed away on 26th April, 2026. The pharmaceutical company filed the mandatory disclosure with BSE and NSE on 27th April, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Senior Management Loss

Mr. Saibal Mukherjee had been serving as Resident Director at the company's Delhi Office and was considered an integral part of the organization. He joined Alembic Pharmaceuticals in 2014 and had been with the company for over a decade at the time of his passing.

The company described his demise as sudden and unexpected, stating it would be an irreparable loss to the organization. All directors and employees have conveyed deep sympathy, sorrow, and condolences to his family during this difficult time.

Regulatory Compliance Details

The disclosure was made in compliance with SEBI regulations and included the required details as per Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026. The formal communication was signed by Company Secretary Manisha Saraf.

Corporate Impact

The loss of a senior management personnel represents a significant organizational change for Alembic Pharmaceuticals. Mr. Mukherjee's role as Resident Director for the Delhi Office made him a key figure in the company's operations in the national capital region.

The company has fulfilled its regulatory obligations by promptly informing the stock exchanges about this material change in senior management personnel, ensuring transparency with stakeholders and compliance with listing requirements.

Alembic Pharmaceuticals has achieved a significant regulatory milestone with the receipt of final approval from the U.S. Food and Drug Administration (FDA) for its Fingolimod Capsules, 0.5 mg. The company announced this development on April 25, 2026, marking an important step forward in expanding its presence in the lucrative American healthcare market.

Regulatory Achievement and Product Details

The final FDA approval for Fingolimod Capsules, 0.5 mg represents a crucial development for Alembic Pharmaceuticals. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation. Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in patients 10 years of age and older.

Market Implications and Commercial Potential

According to IQVIA data, Fingolimod Capsules, 0.5 mg have an estimated market size of US$ 145 million for the twelve months ending December 2025. This substantial market opportunity positions Alembic Pharmaceuticals to capture significant revenue from the American healthcare sector. The final FDA approval demonstrates that the company has met all stringent requirements set by the U.S. regulatory authority, enabling commercial launch subject to market conditions and business strategy.

Strategic Significance and Portfolio Expansion

This FDA approval adds another valuable product to Alembic Pharmaceuticals' growing portfolio of approved medications in the U.S. market. With this latest approval, Alembic now has a cumulative total of 237 ANDA approvals from USFDA, comprising 219 final approvals and 18 tentative approvals. The successful navigation of the FDA approval process reflects the company's commitment to maintaining high-quality manufacturing standards and regulatory compliance, strengthening its competitive position in the generic pharmaceuticals segment.